BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35383950)

  • 21. Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients.
    Cianciolo G; Tondolo F; Barbuto S; Iacovella F; Zavatta G; Altieri P; Grandinetti V; Comai G; Cozzolino M; La Manna G
    Am J Nephrol; 2021; 52(8):611-619. PubMed ID: 34518468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
    Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
    Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use and safety of denosumab in cancer patients.
    Manzaneque A; Chaguaceda C; Mensa M; Bastida C; Creus-Baró N
    Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.
    Pittman K; Antill YC; Goldrick A; Goh J; de Boer RH
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):266-276. PubMed ID: 27862983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
    Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
    Yakugaku Zasshi; 2021; 141(8):1023-1030. PubMed ID: 34334547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of the risk factors associated with hypocalcemia induced by denosumab.
    Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
    Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab-induced hypocalcemia post bariatric surgery-a severe and protracted course: a case report.
    Awang MH; Hatta SFWM; Mohamad AF; Ghani RA
    J Med Case Rep; 2023 Mar; 17(1):73. PubMed ID: 36859300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.
    Kouroglou E; Tsiama V; Dionysopoulou S; Gavriiloglou G; Bora M; Belis K; Proikaki S; Savvidis C; Giannou P; Petras D
    J Musculoskelet Neuronal Interact; 2023 Jun; 23(2):285-289. PubMed ID: 37259667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
    Imatoh T; Sai K; Takeyama M; Hori K; Karayama M; Furuhashi K; Segawa K; Kimura M; Kawakami J; Saito Y
    J Clin Pharm Ther; 2019 Feb; 44(1):62-68. PubMed ID: 30144112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
    Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
    Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
    Hiramatsu R; Ubara Y; Sawa N; Sakai A
    Nephrol Dial Transplant; 2021 Sep; 36(10):1900-1907. PubMed ID: 33544866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
    Bird ST; Smith ER; Gelperin K; Jung TH; Thompson A; Kambhampati R; Lyu H; Zhao H; Zhao Y; Zhu Y; Easley O; Niak A; Wernecke M; Chillarige Y; Zemskova M; Kelman JA; Graham DJ
    JAMA; 2024 Feb; 331(6):491-499. PubMed ID: 38241060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
    Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.
    Spångeus A; Rydetun J; Woisetschläger M
    Osteoporos Int; 2024 Jan; 35(1):173-180. PubMed ID: 37750930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
    Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
    Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic anxiety in a woman with breast cancer receiving denosumab.
    Lin KF; Chen KH; Huang WL
    Gen Hosp Psychiatry; 2015; 37(2):192.e7-8. PubMed ID: 25772947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
    Cowan A; Jeyakumar N; McArthur E; Fleet JL; Kanagalingam T; Karp I; Khan T; Muanda FT; Nash DM; Silver SA; Thain J; Weir MA; Garg AX; Clemens KK
    J Bone Miner Res; 2023 May; 38(5):650-658. PubMed ID: 36970786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia.
    Lambe G; Malvathu R; Thomas HM; Graves A
    Nephrology (Carlton); 2015 Aug; 20(8):583-4. PubMed ID: 26194986
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan.
    Imatoh T; Sai K; Takeyama M; Segawa K; Yamashita T; Nakashima N; Kataoka Y; Yokoi H; Hiramatsu T; Ohe K; Kimura M; Hori K; Kawakami J; Saito Y
    J Clin Pharm Ther; 2019 Oct; 44(5):788-795. PubMed ID: 31282013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.